Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Histological prognostic factors in children with Henoch-Schönlein purpura nephritis.

Delbet JD, Geslain G, Auger M, Hogan J, Salomon R, Peuchmaur M, Deschênes G, Buob D, Parmentier C, Ulinski T.

Pediatr Nephrol. 2019 Nov 6. doi: 10.1007/s00467-019-04363-y. [Epub ahead of print]

PMID:
31696358
2.

CD38-Driven Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma.

Marlein CR, Piddock RE, Mistry JJ, Zaitseva L, Hellmich C, Horton RH, Zhou Z, Auger MJ, Bowles KM, Rushworth SA.

Cancer Res. 2019 May 1;79(9):2285-2297. doi: 10.1158/0008-5472.CAN-18-0773. Epub 2019 Jan 8.

PMID:
30622116
3.

Myeloma-derived macrophage inhibitory factor regulates bone marrow stromal cell-derived IL-6 via c-MYC.

Piddock RE, Marlein CR, Abdul-Aziz A, Shafat MS, Auger MJ, Bowles KM, Rushworth SA.

J Hematol Oncol. 2018 May 16;11(1):66. doi: 10.1186/s13045-018-0614-4.

4.

Measurement of 43Sc and 44Sc production cross-section with an 18MeV medical PET cyclotron.

Carzaniga TS, Auger M, Braccini S, Bunka M, Ereditato A, Nesteruk KP, Scampoli P, Türler A, van der Meulen N.

Appl Radiat Isot. 2017 Nov;129:96-102. doi: 10.1016/j.apradiso.2017.08.013. Epub 2017 Aug 10.

PMID:
28830022
5.

Optimizing the management of patients with spinal myeloma disease.

Molloy S, Lai M, Pratt G, Ramasamy K, Wilson D, Quraishi N, Auger M, Cumming D, Punekar M, Quinn M, Ademonkun D, Willis F, Tighe J, Cook G, Stirling A, Bishop T, Williams C, Boszczyk B, Reynolds J, Grainger M, Craig N, Hamilton A, Chalmers I, Ahmedzai S, Selvadurai S, Low E, Kyriakou C; UK Spinal Myeloma Working Group.

Br J Haematol. 2015 Nov;171(3):332-43. doi: 10.1111/bjh.13577. Epub 2015 Jul 17.

PMID:
26184699
6.

Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.

Murray MY, Zaitseva L, Auger MJ, Craig JI, MacEwan DJ, Rushworth SA, Bowles KM.

Cell Cycle. 2015;14(14):2367-75. doi: 10.1080/15384101.2014.998067. Epub 2015 Jan 7.

7.

Overcoming bortezomib resistance in multiple myeloma.

Murray MY, Auger MJ, Bowles KM.

Biochem Soc Trans. 2014 Aug;42(4):804-8. doi: 10.1042/BST20140126. Review.

PMID:
25109961
8.

New Care Quality Commission inspection regime is under-resourced.

Auger MJ.

BMJ. 2013 Oct 9;347:f6027. doi: 10.1136/bmj.f6027. No abstract available.

PMID:
24108166
9.

Relapsed multiple myeloma in the UK prior to the introduction of novel agents--a response to Koleva et al. (2010).

Quinn J, Percival F, Auger M, Basu S, Chu P, Aldouri M, Lambourne A, Gaugris S, Yong K.

Eur J Cancer Care (Engl). 2011 Sep;20(5):697-9. doi: 10.1111/j.1365-2354.2011.01248.x. Epub 2011 Apr 27. No abstract available.

PMID:
21521387

Supplemental Content

Loading ...
Support Center